MMedication Read More Will you take Wegovy to lose weight?1 August 2025 Wegovy is now available in Singapore more than two years after it was approved by the Health Sciences…
CComputing Read More Microsoft to build world’s most powerful quantum computer in Denmark19 July 2025 Quantum technology is becoming very important for both business and global power. In the last ten years, the…
MMedication Read More GLP-1 drugs for addiction: Confidence grows in new treatment option14 July 2025 WERNERSVILLE, Pa. — To make sense of the reds and greens dancing across a computer monitor displaying a…
MMedication Read More Pancreatitis, Ozempic and exaggerated headlines: A UK alert raises concerns about drug abuse | Health4 July 2025 Last week, many media outlets reported on a press release from the UK Medicines and Healthcare products Regulatory…
EEconomy Read More A big fat fight has just broken out in India24 June 2025 With the launch of Wegovy by Novo Nordisk in India, the country’s obesity drugs sector is all set…
MMedication Read More Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs12 May 2025 People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s…
MMedication Read More Medicines and advertising regulators examine Ozempic maker’s Irish ads11 May 2025 We need your help now Support from readers like you keeps The Journal open. You are visiting us…
MMedication Read More Are ‘Ozempic feet’ real? Here’s what to know8 May 2025 People taking Ozempic and other popular GLP-1 weight loss drugs may expect to feel nausea or stomach pain.…
HHealthcare Read More Novo Nordisk on the back foot ahead of earnings – The Irish Times7 May 2025 Novo Nordisk reports earnings on Wednesday, and for once, Wall Street isn’t holding its breath. Once celebrated for…
MMedication Read More Patients struggle as compounded GLP-1 access rapidly shrinks29 April 2025 The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many…